Specific immunotherapy in hay fever: A practical overview;Die spezifische immuntherapie bei pollenallergie: Ein praxisbezogener überblick

Praxis

Volumn 98, Issue 23, 2009, Pages 1353-1360

  Harder, Dominik ^a   Schmid Grendelmeier, P ^b  

^a Brunnenhof Praxis   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Allergy; Hay fever; IgE; SCIT; SLIT; Specific immunotherapy

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E;

ANAMNESIS; ANTIBODY DETECTION; CLINICAL EFFECTIVENESS; HAY FEVER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MOLECULAR BIOLOGY; PATIENT SAFETY; PATIENT SELECTION; POLLEN ALLERGY; SHORT SURVEY; SKIN TEST; SWITZERLAND;

EID: 72049087718     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157.98.23.1353     Document Type: Short Survey

References (23)

1. Wüthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults. Int Arch Allergy Immunol 1995;106(2):149-56.
2. Wüthrich B. Epidemiologie allergischer Krankheiten in der Schweiz. Ther Umsch 2001;58(5):253-8.
3. Imboden M, Nieters A, Bircher AJ, et al. Cytokine gene polymorphisms and atopic disease in two European cohorts. (ECRHS-Basel and SAPALDIA). Clin Mol Allergy 2006;4:9.
4. Schaub B, Lauener R, von Mutius E. The many faces of the hygiene hypothesis. J Allergy Clin Immunol 2006;117(5):969-77; quiz 78.
5. Traidl-Hoffmann C, Mariani V, Hochrein H, et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 2005;201(4):627-36.
6. Szucs TD, Anderhub HP, Rutishauser M. Determinants of health care costs and patterns of care of asthmatic patients in Switzerland. Schweiz Med Wochenschr 2000;130(9):305-13. (Pubitemid 30136886)
7. Müller U de Weck A, Bodmer R, Gutersohn J, Longoni S, Müllner G, Olgiati D, Pletscher M, Schweri T, Thürlimann W. Good Allergy Practice. Schweiz Aerztezeitung 2000;41:2324-31.
8. Bircher AJ, Wüthrich B, Langauer S, Schmid P. Ficus benjamina, ein perenniales Inhalationsallergen von zunehmender Bedeutung. Schweiz Med Wochenschr 1993;123(22):1153-9. (Pubitemid 23167616)
9. Taramarcaz P, Lambelet B, Clot B, Keimer C, Hauser C. Ragweed (Ambrosia) progression and its health risks: will Switzerland resist this invasion? Swiss Med Wkly 2005;135(37-38):538-48. (Pubitemid 41643756)
10. Mari A, Ballmer-Weber BK, Vieths S. The oral allergy syndrome: improved diagnostic and treatment methods. Curr Opin Allergy Clin Immunol 2005;5(3):267-73. (Pubitemid 40694994)
11. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999;29(7):896-904. (Pubitemid 29317799)
12. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006;6(10):761-71. (Pubitemid 44453462)
13. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007(1):CD001936.
14. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102(4 Pt 1):558-62.
15. Helbling A, Reimers A. Immunotherapy in fungal allergy. Curr Allergy Asthma Rep 2003; 3(5):447-53. (Pubitemid 38899112)
16. Bucher X, Pichler WJ, Dahinden CA, Helbling A. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004;59(12):1272-6. (Pubitemid 39506725)
17. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006;61(2):198-201. (Pubitemid 43381830)
18. Schmid-Grendelmeier P. Pollen als Auslöser von Allergien. Ther Umsch 2001;58(5):285-91. (Pubitemid 33611481)
19. Passalacqua G, Canonica GW. Sublingual immunotherapy: update 2006. Curr Opin Allergy Clin Immunol 2006;6(6):449-54. (Pubitemid 44714158)
20. Eng PA, Hauser C, Schmid-Grendelmeier P, Spertini F, Bircher A. Spezifische Immuntherapie in der Schweiz - sublingual oder subkutan?. Schweiz Med Forum 2004;4:1269-76.
21. Bousquet J, van Cauwenberge P, Ait Khaled N, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy 2006;61(9):1086-96.
22. Malling HJ, Minimishing the risks of allergen-specific Injection immunotherapy. Drug Saf 2000; 23(4):323-332
23. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D. Neubewertung des Risikos von Test- und Therapieallergenen. Bundesgesundheitsbl- Gesundheitsforsch-Gesundheitsschutz 44 (2001):709-718